Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14
November 30 2016 - 4:15PM
Business Wire
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at BMO Capital
Markets’ Prescription for Success Healthcare Conference taking
place December 14 in New York. The Exelixis presentation is
scheduled for 3:40 PM EST/12:40 PM PST.
The presentation will be webcast live and may be accessed via
the Event Calendar page under Investors & Media at
www.exelixis.com. Please connect to the company’s website at least
15 minutes prior to the presentation to ensure adequate time for
any software download that may be require to listen to the webcast.
A replay will also be available at the same location for 14
days.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company
committed to the discovery, development and commercialization of
new medicines with the potential to improve care and outcomes for
people with cancer. Since its founding in 1994, three medicines
discovered at Exelixis have progressed through clinical development
to receive regulatory approval. Currently, Exelixis is focused on
advancing cabozantinib, an inhibitor of multiple tyrosine kinases
including MET, AXL and VEGF receptors, which has shown clinical
anti-tumor activity in more than 20 forms of cancer and is the
subject of a broad clinical development program. Two separate
formulations of cabozantinib have received regulatory approval to
treat certain forms of kidney and thyroid cancer and are marketed
for those purposes as CABOMETYX™ tablets (U.S. and EU) and
COMETRIQ® capsules (U.S. and EU), respectively. Another
Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective
inhibitor of MEK, has been approved in major territories including
the United States and European Union, and is being evaluated for
further potential indications by Roche and Genentech (a member of
the Roche Group) under a collaboration with Exelixis. For more
information on Exelixis, please visit www.exelixis.com or follow
@ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are
registered U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161130006315/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Investor Relations and
Public Affairsshubbard@exelixis.comorFor Exelixis, Inc.Hal Mackins,
415-994-0040hal@torchcomllc.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024